Atypical adenomatous hyperplasia of lung: Its incidence and analysis of clinical, glycohistochemical and structural features including newly defined growth regulators and vascularization

Lung Cancer

Volumn 42, Issue 2, 2003, Pages 171-182

  Kayser, Klaus ^a   Nwoye, Johnson Obiefune ^a   Kosjerina, Zdravko ^b   Goldmann, Thorsten ^c   Vollmer, Ekkehard ^c   Kaltner, Herbert ^d   André, Sabine ^d   Gabius, Hans Joachim ^d  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF NOVI SAD   (Serbia)

^c RESEARCH CENTER BORSTEL   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Atypical adenomatous hyperplasia; Frequency; Lectin; Syntactic structure analysis; Vascularization

Indexed keywords

CANCER GROWTH FACTOR; GALECTIN 1; GALECTIN 3; GALECTIN 7; INTERLEUKIN 2; LECTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PROTEIN; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING SITE; CANCER GRADING; CANCER INCIDENCE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

EID: 0142011059     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00289-7     Document Type: Article

References (50)

1. Carter D. Squamous cell carcinoma of the lung: an update. Semin. Diag. Pathol. 2:1985;226-234.
2. Kayser K. Analytical lung pathology. 1995;Springer Verlag, Heidelberg, New York.
3. Kayser K., Altiner M., Dienemann H., Gabius H.-J. Changes during the last decade in clinical parameters of operated lung carcinoma patients of a center for thoracic surgery and the prognostic significance of TNM, morphometric, cytometric, and glycohistochemical properties. Thorac. Cardiovasc. Surg. 45:1997;196-199.
4. Kawakami S., Sone S., Takashima S., et al. Atypical adenomatous hyperplasia of the lung: correlation between high-resolution CT findings and histopathologic features. Eur. Radiol. 11:2001;811-814.
5. Shimosato Y., Matsuno M.N. Adenocarcinoma of the lung: its development and malignant progression. Lung Cancer. 9:1993;99-108.
6. Carey F.A., Fergusson R.J., Kerr K.M., Lamb D. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a study of 10 cases. Thorax. 47:1992;1041-1043.
7. Nakahara R., Yokose T., Nagai K., et al. Atypical adenomatous hyperplasia of the lung: a clinicopathological study of 118 cases including cases with multiple atypical adenomatous hyperplasia. Thorax. 56:2001;302-305.
8. Weng S., Tsuchiya E., Kasuga T., Sugano H. Incidence of atypical bronchioalveolar cell hyperplasia of the lung: relation to histological subtypes of lung cancer. Virchows. Arch. Pathol. Anatom. 420:1992;463-471.
9. Kosjerina Z, Goldmann T, Kayser K. Frequency in surgical specimens and morphology of atypical alveolar hyperplasia of the lung, Elec. J. Pathol. Histol. 2002;8: 023-04.
10. Yokozaki M., Kodama T., Yokose T., et al. Differentiation of atypical adenomatous hyperplasia and adenocarcinoma of the lung by use of DNA ploidy and morphometric analysis. Mod. Pathol. 9:1996;1156-1164.
11. Niho S., Yokose T., Suzuki K., et al. Monoclonality of atypical adenomatous hyperplasia of the lung. Am. J. Pathol. 154:1999;249-254.
12. Kayser K., Bovin N.V., Korchagina E.Y., et al. Correlation of expression of binding sites for synthetic blood group A-, B- and H-trisaccharides and for sarcolectin with survival of patients with bronchial carcinoma. Eur. J. Cancer. 30A:1994;653-657.
13. Kayser K., Andre S., Bovin N.V., et al. Preneoplasia-associated expression of calcyclin and of binding sites for synthetic blood group A/H trisaccharide - exposing neoglycoconjugates in human lung. Cancer Biochem. Biophys. 15:1997;235-243.
14. Chapman A.D., Kerr K.M. The association between atypical adenomatous hyperplasia and primary lung cancer. Br. J. Cancer. 83:2000;632-636.
15. Mori M., Rao S.K., Popper H.H., et al. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod. Pathol. 14:2001;72-84.
16. Gabius H.-J., Kohnke-Godt B., Leichsenring M., Bardosi A. Heparin-binding lectin of human placenta as a tool for histochemical ligand localization and ligand isolation. J. Histochem. Cytochem. 39:1991;1249-1256.
17. Zeng F.-Y., Gabius H.-J. Carbohydrate-binding specificity of calcyclin and its expression in human tissues and leukemic cells. Arch. Biochem. Biophys. 289:1991;137-144.
18. André S., Kojima S., Yamazaki N., et al. Galectins-1 and -3 and their ligands in tumor biology. J. Cancer Res. Clin. Oncol. 125:1999;461-474.
19. Kayser K., Zink S., André S., et al. Primary colorectal carcinomas and their intrapulmonary metastases: clinical, glyco-, immuno- and lectin histochemical, nuclear and syntactic structure analysis with emphasis on correlation with period of occurrence of metastases and survival. Apmis. 110:2002;435-446.
20. Rorive S., Eddafali B., Fernandez S., et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implication. Mod. Pathol. 15:2002;1294-1301.
21. Wollina U., Graefe T., Feldrappe S., et al. Galectin fingerprinting by immuno- and lectin histochemistry in cutaneous lymphoma. J. Cancer Res. Clin. Oncol. 128:2002;103-110.
22. André S., Pieters R.J., Vrasidas I., et al. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters and cell surface glycoconjugates. ChemBioChem. 2:2001;822-830.
23. Kayser K., Kayser G., Bovin N.V., et al. Quantitative evaluation of ligandohistochemistry with cytoplasmic markers: program structure and application to lung carcinomas. Elec. J. Pathol. Histol. 1:1995;954-1002.
24. Kayser K., Gabius H.-J. The application of thermodynamic principles to histochemical and morphometric tissue research: principles and practical outline with focus on the glycosciences. Cell Tissue Res. 296:1999;443-455.
25. Kayser K., Gabius H.-J. Graph theory and the entropy concept in histochemistry. Theoretical considerations, application in histopathology and the combination with receptor-specific approaches. Prog. Histochem. Cytochem. 32:1997;1-106.
26. Kayser K., Kayser G., Eichhorn S., et al. Association of prognosis in surgically treated lung cancer patients with cytometric, histometric and ligand histochemical properties: with an emphasis on structural entropy. Anal. Quant. Cytol. Histol. 20:1998;313-320.
27. Colby TV, Wistuba II, Gazdar A. Precursors to pulmonary neoplasia, Adv. Anat. Pathol. 1998;5: 205-215.
28. Friedrich G. Periphere Lungenkrebse auf dem Boden pleuranaher Narben. Virchows Arch. Pathol. Anat. 304:1939;230-247.
29. Shimosato Y., Kodoma T., Kameya Y. Morphogenesis of peripheral type adenocarcinoma of the lung. Shimosato Y. Morphogenesis of lung cancer wall. 1982;65-89 CRC Press, Boca Raton, FL.
30. Miller R. Bronchioloalveolar cell adenomas. Am. J. Surg. Pathol. 14:1990;904-912.
31. Yokose T., Doi M., Tanno K., et al. Atypical adenomatous hyperplasia of the lung in autopsy cases. Lung Cancer. 33:2001;155-161.
32. Weng S., Tsuchiya E., Satoh Y., et al. Multiple atypical adenomatous hyperplasia of type II pneumonocytes and bronchiolo-alveolar carcinoma. Histopathology. 16:1990;101-103.
33. Nomori H., Horio H., Naruke T., et al. A case of multiple atypical adenomatous hyperplasia of the lung detected by computed tomography. Jpn. J. Clin. Oncol. 31:2001;514-516.
34. Kitamura H., Kameda Y., Ito T., Hayashi H. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am. J. Clin. Pathol. 111:1999;610-622.
35. Kitamura H., Kameda Y., Nakamura N., et al. Atypical adenomatous hyperplasia and bronchoalveolar lung carcinoma. Analysis by morphometry and the expressions of p53 and carcinoembryonic antigen. Am. J. Surg. Pathol. 20:1996;553-562.
36. Mitchell R.A., et al. Macrophage migration inhibitory factor (MIF) sustains macrophage porinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA. 99:2002;345-350.
37. Hudson J.D., et al. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J. Exp. Med. 190:1999;1375-1382.
38. Kamimura A., et al. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung. Cancer. 89:2000;334-341.
39. Ogawa H., et al. An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumor-associated angiogenesis. Cytokine. 12:2000;309-314.
40. Gabius H.-J. Concepts of tumor lectinology. Cancer Invest. 15:1997;454-464.
41. Danguy A., Camby I., Kiss R. Galectins and cancer. Biochim. Biophys. Acta. 1572:2002;285-293.
42. Gabius H.-J., André S., Kaltner H., Siebert H.-C. The sugar code: functional lectinomics. Biochim. Biophys. Acta. 1572:2002;165-177.
43. Rabinovich G.A., Rubinstein N., Toscano M. Role of galectins in inflammatory and immunomodulatory processes. Biochim. Biophys. Acta. 1572:2002;274-284.
44. Lahm H., André S., Höflich A., et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J. Cancer Res. Clin. Oncol. 127:2001;375-386.
45. Elad-Sfadia G., Haklai R., Ballan E., et al. Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase. J. Biol. Chem. 277:2002;37 169-37 175.
46. Gabius H.-J. Probing the cons and pros of lectin-induced immuno-modulation. Biochimie. 83:2001;659-666.
47. Kopitz J., von Reitzenstein C., André S., et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J. Biol. Chem. 276:2001;35 917-35 923.
48. Gabius H.-J. Glycohistochemistry: the why and how of detection and localization of endogenous lectins. Anat. Histol. Embryol. 30:2001;3-31.
49. Kayser K., Berthold S., Eichhorn S., et al. Application of attributed graphs in diagnostic pathology. Anal. Quant. Cytol. Histol. 18:1996;286-292.
50. Kayser K., Richter B., Stryciak R., et al. Positive and negative correlations between vascularization and parameters derived from integrated nuclear fluorescence and syntactic structure analysis in human lung carcinomas. Anal. Cell. Pathol. 15:1997;73-83.